1. Introduction and Background
Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight 1419.53 Da) derived from a partial sequence of human gastric juice protein. First isolated and characterised by Sikiric and colleagues at the University of Zagreb, BPC-157 has been the subject of extensive preclinical investigation over the past three decades, yielding a substantial body of literature on its pharmacological properties (Sikiric et al., 2014). Unlike many endogenous peptides, BPC-157 demonstrates notable stability in human gastric juice without the requirement for a carrier molecule, a property that has distinguished it within the broader landscape of bioactive peptides (Sikiric et al., 2020).
The peptide was originally identified through systematic investigation of cytoprotective factors present in gastric secretions. Early research established that BPC-157 is not found in isolation within the native proteome but rather represents a stable fragment of a larger parent protein. Its characterisation as a "body protection compound" derives from the broad organoprotective effects observed across multiple organ systems in animal models, spanning gastrointestinal, musculoskeletal, vascular, and neurological tissues (Sikiric et al., 2011). This breadth of activity has generated considerable interest within the research community, although it is important to note that the majority of published findings derive from preclinical models, and human clinical trial data remain limited.
2. Mechanism of Action
2.1 Nitric Oxide System Modulation
A central aspect of BPC-157 pharmacology involves its interaction with the nitric oxide (NO) system. Experimental evidence has demonstrated that BPC-157 modulates NO synthesis and signalling pathways in a context-dependent manner, counteracting both NO-excess and NO-deficiency states (Sikiric et al., 2014). In models of NO synthase (NOS) blockade, BPC-157 administration attenuated the hypertensive and tissue-damaging effects typically associated with NOS inhibition. Conversely, in states of NO overproduction, the peptide demonstrated protective effects against NO-mediated cytotoxicity. This bidirectional modulatory capacity has been proposed as a unifying mechanism underlying the peptide's diverse tissue-protective effects, although the precise molecular intermediaries through which BPC-157 engages the NO pathway remain under active investigation.
2.2 Vascular Endothelial Growth Factor and Angiogenesis
Research has established that BPC-157 exerts significant pro-angiogenic effects, a property closely linked to its tissue-reparative actions. Hsieh et al. (2017) demonstrated that BPC-157 promotes angiogenesis through activation of the vascular endothelial growth factor receptor 2 (VEGFR2) signalling cascade. Using human umbilical vein endothelial cells (HUVECs), the investigators observed that BPC-157 treatment upregulated VEGFR2 expression and stimulated downstream phosphorylation events, including activation of the Akt and ERK1/2 pathways (Hsieh et al., 2017). These findings suggest that BPC-157 may facilitate tissue repair in part by promoting the formation of new vasculature at sites of injury, thereby enhancing oxygen and nutrient delivery to damaged tissues.
Complementary work by Seiwerth et al. (2014) characterised the effects of BPC-157 on blood vessel integrity and function across a range of experimental vascular injury models. The peptide demonstrated a capacity to promote vessel formation while simultaneously protecting existing vasculature against ischaemic and traumatic insults (Seiwerth et al., 2014). These vascular effects are considered to be a key component of the peptide's broader organoprotective profile.
2.3 Growth Factor and Cytokine Interactions
Beyond VEGF signalling, BPC-157 has been reported to influence the expression and activity of several additional growth factors pertinent to tissue repair. Studies have documented effects on fibroblast growth factor (FGF), epidermal growth factor (EGF), and transforming growth factor-beta (TGF-β) pathways, suggesting a multi-target mechanism of action rather than engagement with a single discrete receptor (Sikiric et al., 2020). This polypharmacological profile, while complicating mechanistic elucidation, may account for the consistency of reparative effects observed across disparate tissue types.
3. Research on Tissue Repair and Wound Healing
3.1 Tendon and Ligament Repair
The effects of BPC-157 on connective tissue healing have been investigated in several well-characterised animal models. Cerovecki et al. (2010) examined the influence of BPC-157 on medial collateral ligament healing in a rat transection model. Histological and biomechanical analyses revealed that BPC-157-treated animals exhibited significantly enhanced ligament repair relative to controls, with improved collagen organisation, increased cellularity at the repair site, and superior functional recovery as measured by load-to-failure testing (Cerovecki et al., 2010).
Chang et al. (2011) further elucidated the cellular mechanisms underlying BPC-157-mediated tendon repair. Using an Achilles tendon explant culture system, the investigators demonstrated that BPC-157 promoted tendon fibroblast outgrowth, enhanced cell survival under stress conditions, and stimulated directional cell migration toward the injury site. These findings were corroborated by in vivo data showing accelerated functional recovery in BPC-157-treated animals following tendon transection (Chang et al., 2011). The promotion of cellular migration and proliferation at injury sites represents a plausible mechanism through which the peptide facilitates structural tissue repair.
3.2 Skeletal Muscle Healing
Investigation of BPC-157 in muscle injury models has produced analogous findings. Staresinic et al. (2006) assessed the effects of BPC-157 on transected quadriceps muscle in rats, reporting significantly improved functional recovery and enhanced histological repair in treated animals. Morphometric analysis demonstrated increased muscle fibre regeneration, reduced fibrotic scar formation, and improved neuromuscular junction recovery in the BPC-157 group compared to vehicle-treated controls (Staresinic et al., 2006). These observations suggest that BPC-157 may promote regenerative rather than fibrotic repair pathways in skeletal muscle tissue.
3.3 Cutaneous Wound Healing
The wound healing properties of BPC-157 have also been evaluated in dermal injury models. Huang et al. (2015) investigated the effects of BPC-157 on alkali-burn wounds, demonstrating accelerated wound closure, enhanced granulation tissue formation, and increased neovascularisation in treated animals. In vitro experiments conducted as part of the same study confirmed that BPC-157 promoted fibroblast proliferation, keratinocyte migration, and endothelial tube formation (Huang et al., 2015). The convergence of pro-migratory, pro-proliferative, and pro-angiogenic effects in cutaneous tissue supports a multi-modal mechanism of wound healing enhancement.
4. Gastrointestinal Protection
Given its derivation from gastric juice protein, the gastrointestinal effects of BPC-157 have received particular attention. The peptide has demonstrated cytoprotective activity across a wide range of gastrointestinal injury models, including those induced by ethanol, non-steroidal anti-inflammatory drugs (NSAIDs), and various cytotoxic agents (Sikiric et al., 2011).
Sikiric and colleagues have proposed that BPC-157 represents a novel mediator of what they term "organoprotection," extending the classical concept of gastric cytoprotection described by Robert. In this framework, BPC-157 is hypothesised to engage endogenous protective mechanisms that operate across organ boundaries, rather than being limited to mucosal defence alone (Sikiric et al., 2010). Experimental data have demonstrated that BPC-157 administration attenuates gastric lesion formation, promotes mucosal integrity, and accelerates healing of established ulcerative lesions in various rodent models. The peptide has also shown protective effects against intestinal anastomosis complications and inflammatory bowel disease-like pathology in animal studies (Sikiric et al., 2020).
The gastrointestinal cytoprotective effects of BPC-157 appear to involve multiple complementary mechanisms, including modulation of prostaglandin synthesis, maintenance of mucosal blood flow through NO-dependent pathways, and upregulation of growth factor expression within the gastrointestinal mucosa. The peptide's inherent stability in gastric acid represents a pharmacologically favourable characteristic for gastrointestinal applications, as it suggests resistance to the proteolytic degradation that limits the oral bioavailability of many peptide-based compounds (Sikiric et al., 2014).
5. Pharmacological Properties
BPC-157 exhibits several pharmacological characteristics that distinguish it from other bioactive peptides under investigation. Its stability in human gastric juice, as noted above, is atypical for peptides of this size and has been consistently documented across experimental conditions. Toxicology studies conducted in rodent models have reported a favourable safety profile, with no observed lethal dose (LD1) identified even at very high experimental doses (Sikiric et al., 2011).
The peptide has demonstrated efficacy via multiple routes of administration in animal studies, including intraperitoneal, intragastric, topical, and local application directly to injury sites. This route flexibility is notable and may relate to the peptide's pleiotropic mechanism of action, engaging local tissue repair pathways regardless of the route by which it reaches the target tissue. BPC-157 activity has been observed at microgram and nanogram doses in rodent models, suggesting high potency relative to its molecular weight (Sikiric et al., 2020).
6. Neuroprotective and Central Nervous System Effects
Emerging research has extended the investigation of BPC-157 into central nervous system (CNS) models. Vukojevic et al. (2022) reviewed the accumulating evidence for BPC-157 interactions with dopaminergic, serotonergic, GABAergic, and opioid systems in the CNS. Preclinical studies have reported that BPC-157 counteracts behavioural disturbances induced by dopaminergic and serotonergic agents, attenuates seizure activity in certain models, and demonstrates neuroprotective effects against traumatic brain injury and ischaemic insults in rodents (Vukojevic et al., 2022). These CNS effects, while preliminary, expand the potential research applications of BPC-157 beyond peripheral tissue repair and gastrointestinal protection.
7. Current Research Directions and Limitations
Despite the extensive preclinical literature, several important limitations and open questions persist within BPC-157 research. The overwhelming majority of published studies have been conducted in rodent models, and the absence of large-scale, controlled human clinical trials represents a significant gap in the evidence base. While one clinical trial (PL 14736) for inflammatory bowel disease reached early-phase investigation, comprehensive human efficacy and pharmacokinetic data remain unavailable in the peer-reviewed literature.
A notable characteristic of the BPC-157 literature is the predominant contribution from a single research group based at the University of Zagreb, led by Predrag Sikiric. While the consistency of findings across numerous studies and experimental models lends a degree of internal validity, independent replication by additional research groups is essential for establishing the robustness and generalisability of reported effects. Recent years have seen increasing independent investigation, including the work of Hsieh et al. (2017) and Huang et al. (2015) from separate institutions, which has begun to address this limitation (Hsieh et al., 2017); (Huang et al., 2015).
Current research directions include elucidation of the specific receptor or receptors through which BPC-157 initiates its intracellular signalling cascades, characterisation of structure-activity relationships to identify the minimal active sequence, and investigation of potential synergistic effects with established therapeutic agents. The peptide's interactions with the NO system, FAK-paxillin pathway, and VEGFR2 signalling represent active areas of mechanistic inquiry (Sikiric et al., 2014); (Hsieh et al., 2017). Additionally, the development of suitable formulations for human investigation, particularly regarding optimisation of oral bioavailability and establishment of pharmacokinetic parameters in humans, represents a priority for translational research efforts.
Musculoskeletal & Spinal Animal-Model Research
A substantial share of the BPC-157 preclinical literature concerns connective-tissue and musculoskeletal injury models. The studies summarised here are reported as published — describing each research group's experimental design and observations in laboratory animals or in vitro. They are not protocols, recommendations, or guidance for administration to any animal or person; Neovia products are supplied strictly for in-vitro laboratory research.
Tendon & Ligament Models
Staresinic et al. (2003) reported, in a rat Achilles-tendon transection model run alongside a parallel in-vitro tendocyte culture, accelerated tendon healing in vivo and stimulated tendocyte growth in vitro versus controls (Staresinic et al., 2003). Krivic et al. (2006), using a rat Achilles tendon-to-bone detachment model, reported promoted tendon-to-bone healing and counteraction of corticosteroid-aggravated healing versus controls (Krivic et al., 2006). In a subsequent rat Achilles tendon-to-bone transection model, Krivic et al. (2008) reported improved early functional recovery of the tendon-to-bone unit with BPC 157, contrasting with methylprednisolone (Krivic et al., 2008). Cerovecki et al. (2010), in a rat medial collateral ligament transection model, reported functional, biomechanical, macroscopic and histological improvement in ligament healing over 90 days versus controls (Cerovecki et al., 2010). Chang et al. (2011), in an in-vitro rat Achilles tendon explant and tendon fibroblast model, reported that BPC 157 accelerated tendon-explant outgrowth and increased fibroblast survival and migration (Chang et al., 2011).
Bone, Joint & Muscle Models
Sebecic et al. (1999), in a rabbit segmental radius bone-defect model, reported improved osteogenic healing of the defect with BPC-157, comparable to bone marrow or autologous cortical bone implantation (Sebecic et al., 1999). Novinscak et al. (2008), in a rat gastrocnemius muscle crush-injury model, reported accelerated post-injury muscle healing macroscopically, microscopically, functionally and by serum enzyme activity versus controls (Novinscak et al., 2008). Dedicated rat-knee-osteoarthritis primary studies were not among the reviewed literature, so the joint-area evidence reported here is adjacent — drawn from the bone-defect and ligament models above rather than from a direct osteoarthritis model.
Spinal Cord & Peripheral-Nerve Models
Gjurasin et al. (2010), in a rat transected sciatic nerve model, reported faster and more homogeneous axonal regeneration, improved electrophysiology and walking, and absence of autotomy versus controls (Gjurasin et al., 2010). Perovic et al. (2019), in a rat sacrocaudal spinal cord compression-injury model using a single intraperitoneal injection 10 minutes post-injury, reported improved motor function, resolved spasticity by day 15, and counteraction of microscopic spinal-cord damage (Perovic et al., 2019).
These observations derive from animal models and in-vitro systems. They have not been established in controlled human or veterinary clinical trials, and the compound is not approved for therapeutic or veterinary use. The literature is presented here for research context only.
In summary, BPC-157 represents a pentadecapeptide with a broad preclinical evidence base supporting tissue-protective and reparative properties across multiple organ systems. Its distinctive stability, multi-target pharmacology, and favourable preclinical safety profile make it a compound of considerable research interest. However, the translation of these preclinical observations into validated human applications requires further investigation through rigorous, controlled clinical trials conducted by independent research groups.